Research Article 
Impact of apolipoprotein ɛ4–cerebrospinal fluid beta-amyloid interaction on hippocampal volume loss over 1 year in mild cognitive impairment
Gloria C. Chiang, Philip S. Insel, Duygu Tosun, Norbert Schuff, Diana Truran- Sacrey, Sky T. Raptentsetsang, Paul M. Thompson, Eric M. Reiman, Clifford R. Jack, Nick C. Fox, William J. Jagust, Danielle J. Harvey, Laurel A. Beckett, Anthony Gamst, Paul S. Aisen, Ron C. Petersen and Michael W. Weiner
Alzheimer`s & Dementia, 2011, 7(5), 514-520. DOI: 10.1016/j.jalz.2010.12.010
Abstract
Background The majority of studies relating amyloid pathology with brain volumes have been cross-sectional. Apolipoprotein ɛ4 (APOE ɛ4), a genetic risk factor for Alzheimer‘s disease, is also known to be associated with hippocampal volume loss. No studies have considered the effects of amyloid pathology and APOE ɛ4 together on longitudinal volume loss. Methods We evaluated whether an abnormal level of cerebrospinal fluid beta-amyloid (CSF Aβ) and APOE ɛ4 carrier status were independently associated with greater hippocampal volume loss over 1 year. We then assessed whether APOE ɛ4 status and CSF Aβ acted synergistically, testing the significance of an interaction term in the regression analysis. We included 297 participants: 77 cognitively normal, 144 with mild cognitive impairment (MCI), and 76 with Alzheimer‘s disease. Results An abnormal CSF Aβ level was found to be associated with greater hippocampal volume loss over 1 year in each group. APOE ɛ4 was associated with hippocampal volume loss only in the cognitively normal and MCI groups. APOE ɛ4 carriers with abnormal CSF Aβ in the MCI group acted synergistically to produce disproportionately greater volume loss than noncarriers. Conclusion Baseline CSF Aβ predicts progression of hippocampal volume loss. APOE ɛ4 carrier status amplifies the degree of neurodegeneration in MCI. Understanding the effect of interactions between genetic risk and amyloid pathology will be important in clinical trials and our understanding of the disease process.
ASCI-ID: 285-162
Similar Articles
Plasma ceramides are altered in mild cognitive impairment and predict cognitive decline and hippocampal volume loss
Alzheimer`s & Dementia, 2010, 6(5), 378-385. DOI: 10.1016/j.jalz.2010.03.014
Japanese Alzheimer’s Disease Neuroimaging Initiative: Present status and futureAlzheimer`s & Dementia, 2010, 6(3), 297-299. DOI: 10.1016/j.jalz.2010.03.011
Commentary on `A roadmap for the prevention of dementia II: Leon Thal Symposium 2008.` Establishing a national biomarker database: Utility and incentivesAlzheimer`s & Dementia, 2009, 5(2), 108-113. DOI: 10.1016/j.jalz.2009.01.015
Fornix integrity and hippocampal volume predict memory decline and progression to Alzheimer‘s diseaseAlzheimer`s & Dementia, 2012, 8(2), 105-113. DOI: 10.1016/j.jalz.2011.05.2416
Effect of human cerebrospinal fluid sampling frequency on amyloid-β levelsAlzheimer`s & Dementia, 2012, 8(4), 295-303. DOI: 10.1016/j.jalz.2011.05.900
Decreased gray matter diffusivity: A potential early Alzheimer‘s disease biomarker?Alzheimer`s & Dementia, 2013, 9(1), 93-97. DOI: 10.1016/j.jalz.2011.11.004
Discriminatory and predictive capabilities of enzyme-linked immunosorbent assay and multiplex platforms in a longitudinal Alzheimer‘s disease studyAlzheimer`s & Dementia, 2013, 9(3), 276-283. DOI: 10.1016/j.jalz.2012.01.004
β-Site amyloid precursor protein–cleaving enzyme 1 activity is related to cerebrospinal fluid concentrations of sortilin-related receptor with A-type repeats, soluble amyloid precursor protein, and tauAlzheimer`s & Dementia, 2013, 9(4), 386-391. DOI: 10.1016/j.jalz.2012.01.015
Amyloid positron emission tomography with 18F-flutemetamol and structural magnetic resonance imaging in the classification of mild cognitive impairment and Alzheimer‘s diseaseAlzheimer`s & Dementia, 2013, 9(3), 295-301. DOI: 10.1016/j.jalz.2012.01.006
White matter is altered with parental family history of Alzheimer’s diseaseAlzheimer`s & Dementia, 2010, 6(5), 394-403. DOI: 10.1016/j.jalz.2009.11.003
White matter is altered with parental family history of Alzheimer’s diseaseAlzheimer`s & Dementia, 2010, 6(5), 394-403. DOI: 10.1016/j.jalz.2009.11.003
Cerebral atrophy, apolipoprotein E ε4, and rate of decline in everyday function among patients with amnestic mild cognitive impairmentAlzheimer`s & Dementia, 2010, 6(5), 404-411. DOI: 10.1016/j.jalz.2010.02.003
The Alzheimer’s Disease Neuroimaging Initiative: Annual change in biomarkers and clinical outcomesAlzheimer`s & Dementia, 2010, 6(3), 257-264. DOI: 10.1016/j.jalz.2010.03.002
The Alzheimer’s Disease Neuroimaging Initiative: Progress report and future plansAlzheimer`s & Dementia, 2010, 6(3), 202-211. DOI: 10.1016/j.jalz.2010.03.007
The Alzheimer’s Disease Neuroimaging Initiative: Perspectives of the Industry Scientific Advisory BoardAlzheimer`s & Dementia, 2010, 6(3), 286-290. DOI: 10.1016/j.jalz.2010.03.010
Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: Recommendations from the Alzheimer‘s Association Research Roundtable WorkgroupAlzheimer`s & Dementia, 2011, 7(4), 367-385. DOI: 10.1016/j.jalz.2011.05.2351
Magnetic resonance imaging-measured atrophy and its relationship to cognitive functioning in vascular dementia and Alzheimer‘s disease patientsAlzheimer`s & Dementia, 2011, 7(5), 493-500. DOI: 10.1016/j.jalz.2011.01.004
Direct comparison of fluorodeoxyglucose positron emission tomography and arterial spin labeling magnetic resonance imaging in Alzheimer's diseaseAlzheimer`s & Dementia, 2012, 8(1), 51-59. DOI: 10.1016/j.jalz.2011.06.003
An investigation of PreMCI: Subtypes and longitudinal outcomesAlzheimer`s & Dementia, 2012, 8(3), 172-179. DOI: 10.1016/j.jalz.2011.03.002
Vascular risk factors, apolipoprotein E, and hippocampal decline on magnetic resonance imaging over a 10-year follow-upAlzheimer`s & Dementia, 2012, 8(5), 417-425. DOI: 10.1016/j.jalz.2011.07.005
Greater regional brain atrophy rate in healthy elderly subjects with a history of cigarette smokingAlzheimer`s & Dementia, 2012, 8(6), 513-519. DOI: 10.1016/j.jalz.2011.10.006
Decreased gray matter diffusivity: A potential early Alzheimer‘s disease biomarker?Alzheimer`s & Dementia, 2013, 9(1), 93-97. DOI: 10.1016/j.jalz.2011.11.004
Amyloid positron emission tomography with 18F-flutemetamol and structural magnetic resonance imaging in the classification of mild cognitive impairment and Alzheimer‘s diseaseAlzheimer`s & Dementia, 2013, 9(3), 295-301. DOI: 10.1016/j.jalz.2012.01.006